Effect of Kataphala bark (Myrica nagi) to alleviate breathlessness in individuals with Chronic Obstructive Pulmonary Disease.

Evaluating the Efficacy of Kataphala (Myrica Nagi) in Cigarette Smoke-Induced Chronic Obstructive Pulmonary Disease in Mice and Clinical Study - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/02/080052

Enrollment

Registered

2025-02-07

Start date

Unknown

Completion date

Unknown

Last updated

2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J441- Chronic obstructive pulmonary disease with (acute) exacerbation

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Patients who will agree to follow the study protocol of the informed consent and patients who have the following signs and symptoms i)cough with sputum ii) wheezing sound iii) dyspnoea on deep velocity iv)breathlessness

Exclusion criteria

Exclusion criteria: below 35 years and above 50 years pre-existing diabetes, hypertension and other systemic disorders pregnancy cardiac disease tuberculosis sexually transmitted disease prostatic hypertrophy hepatic disease HIV positive

Design outcomes

Primary

Measure	Time frame
To Evaluate the efficacy of Kataphala bark by monitoring the signs and symptoms of patients suffering from Chronic Obstructive Pulmonary Disease.Timepoint: 28 days	—

Secondary

Measure	Time frame
Effect of test drug on quality of life among the patients suffering from Chronic Obstructive Pulmonary DiseaseTimepoint: 28 days	—

Countries

India

Contacts

Public ContactDr Haiqua Naushin

Institute of Post Graduate Ayurvedic Education and Research at S.V.S.P.

atipgaer@gmail.com9874849650

Outcome results